217 related articles for article (PubMed ID: 36309492)
1. Differential trafficking of ligands trogocytosed via CD28 versus CTLA4 promotes collective cellular control of co-stimulation.
Zenke S; Sica MP; Steinberg F; Braun J; Zink A; Gavrilov A; Hilger A; Arra A; Brunner-Weinzierl M; Elling R; Beyersdorf N; Lämmermann T; Smulski CR; Rohr JC
Nat Commun; 2022 Oct; 13(1):6459. PubMed ID: 36309492
[TBL] [Abstract][Full Text] [Related]
2. CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis.
Xu X; Dennett P; Zhang J; Sherrard A; Zhao Y; Masubuchi T; Bui JD; Chen X; Hui E
J Exp Med; 2023 Jul; 220(7):. PubMed ID: 37042938
[TBL] [Abstract][Full Text] [Related]
3. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
Lane P
Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
[TBL] [Abstract][Full Text] [Related]
4. Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
Lazetic S; Leong SR; Chang JC; Ong R; Dawes G; Punnonen J
J Biol Chem; 2002 Oct; 277(41):38660-8. PubMed ID: 12167647
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28.
Lin H; Rathmell JC; Gray GS; Thompson CB; Leiden JM; Alegre ML
J Exp Med; 1998 Jul; 188(1):199-204. PubMed ID: 9653096
[TBL] [Abstract][Full Text] [Related]
6. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.
Bai XF; Liu J; May KF; Guo Y; Zheng P; Liu Y
Blood; 2002 Apr; 99(8):2880-9. PubMed ID: 11929778
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.
Guo Y; Wu Y; Zhao M; Kong XP; Liu Y
J Exp Med; 1995 Apr; 181(4):1345-55. PubMed ID: 7535334
[TBL] [Abstract][Full Text] [Related]
8. CD28/B7 costimulation: a review.
Greenfield EA; Nguyen KA; Kuchroo VK
Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
[TBL] [Abstract][Full Text] [Related]
9. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.
Fargeas CA; Truneh A; Reddy M; Hurle M; Sweet R; Sékaly RP
J Exp Med; 1995 Sep; 182(3):667-75. PubMed ID: 7544393
[TBL] [Abstract][Full Text] [Related]
10. CD28-specific antibody prevents graft-versus-host disease in mice.
Yu XZ; Bidwell SJ; Martin PJ; Anasetti C
J Immunol; 2000 May; 164(9):4564-8. PubMed ID: 10779758
[TBL] [Abstract][Full Text] [Related]
11. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
[TBL] [Abstract][Full Text] [Related]
12. Regulation of T cell activation by CD28 and CTLA4.
Noel PJ; Boise LH; Thompson CB
Adv Exp Med Biol; 1996; 406():209-17. PubMed ID: 8910687
[TBL] [Abstract][Full Text] [Related]
13. CD28, CTLA-4 and their ligands: who does what and to whom?
Sansom DM
Immunology; 2000 Oct; 101(2):169-77. PubMed ID: 11012769
[No Abstract] [Full Text] [Related]
14. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
Fallarino F; Fields PE; Gajewski TF
J Exp Med; 1998 Jul; 188(1):205-10. PubMed ID: 9653097
[TBL] [Abstract][Full Text] [Related]
15. Fine mapping of an IgE-controlling gene on chromosome 2q: Analysis of CTLA4 and CD28.
Howard TD; Postma DS; Hawkins GA; Koppelman GH; Zheng SL; Wysong AK; Xu J; Meyers DA; Bleecker ER
J Allergy Clin Immunol; 2002 Nov; 110(5):743-51. PubMed ID: 12417883
[TBL] [Abstract][Full Text] [Related]
16. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice.
Li J; Semple K; Suh WK; Liu C; Chen F; Blazar BR; Yu XZ
Biol Blood Marrow Transplant; 2011 Jul; 17(7):962-9. PubMed ID: 21447398
[TBL] [Abstract][Full Text] [Related]
17. Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac disease.
Popat S; Hearle N; Hogberg L; Braegger CP; O'Donoghue D; Falth-Magnusson K; Holmes GK; Howdle PD; Jenkins H; Johnston S; Kennedy NP; Kumar PJ; Logan RF; Marsh MN; Mulder CJ; Torinsson Naluai A; Sjoberg K; Stenhammar L; Walters JR; Jewell DP; Houlston RS
Ann Hum Genet; 2002 Mar; 66(Pt 2):125-37. PubMed ID: 12174216
[TBL] [Abstract][Full Text] [Related]
18. In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity.
Denfeld RW; Dietrich A; Wuttig C; Tanczos E; Weiss JM; Vanscheidt W; Schöpf E; Simon JC
Int J Cancer; 1995 Jul; 62(3):259-65. PubMed ID: 7543078
[TBL] [Abstract][Full Text] [Related]
19. CD28 co-stimulation results in down-regulation of lymphotactin expression in human CD4(+) but not CD8(+) T cells via an IL-2-dependent mechanism.
Olive D; Cerdan C
Eur J Immunol; 1999 Aug; 29(8):2443-53. PubMed ID: 10458758
[TBL] [Abstract][Full Text] [Related]
20. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.
Greene JL; Leytze GM; Emswiler J; Peach R; Bajorath J; Cosand W; Linsley PS
J Biol Chem; 1996 Oct; 271(43):26762-71. PubMed ID: 8900156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
